T. Crockett
Founder at KalVista Pharmaceuticals Ltd.
Net worth: 3 M $ as of 2024-03-30
T. Crockett active positions
Companies | Position | Start | End |
---|---|---|---|
Vantia Ltd.
Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom. | Director/Board Member | 2010-03-31 | - |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Director/Board Member | 2010-12-31 | - |
Chief Executive Officer | 2010-12-31 | - | |
Founder | 2010-12-31 | - |
Career history of T. Crockett
Former positions of T. Crockett
Companies | Position | Start | End |
---|---|---|---|
KALVISTA PHARMACEUTICALS, INC. | Director/Board Member | 2016-11-20 | 2024-03-05 |
Chief Executive Officer | 2016-11-20 | 2024-03-05 | |
Founder | 2004-03-25 | 2024-03-05 | |
ZARS Pharma, Inc.
ZARS Pharma, Inc. Pharmaceuticals: MajorHealth Technology ZARS Pharma, Inc. develops and distributes drugs. It is a specialty pharmaceutical company focused on the development and commercialization of topically administered drugs, primarily for the treatment of pain, using its proprietary drug delivery technologies. The company was founded by Jie Zhang, Theodore H. Stanley, Larry D. Rigby and Michael A. Ashburn in 1996 and is headquartered in Salt Lake City, UT. | Corporate Officer/Principal | 1999-07-31 | - |
Training of T. Crockett
University of Utah | Undergraduate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Harvard Business School | Undergraduate Degree |
Statistics
International
United States | 6 |
United Kingdom | 3 |
Operational
Director/Board Member | 3 |
Chief Executive Officer | 2 |
Founder | 2 |
Sectoral
Health Technology | 4 |
Consumer Services | 4 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
KALVISTA PHARMACEUTICALS, INC. | Health Technology |
Private companies | 3 |
---|---|
ZARS Pharma, Inc.
ZARS Pharma, Inc. Pharmaceuticals: MajorHealth Technology ZARS Pharma, Inc. develops and distributes drugs. It is a specialty pharmaceutical company focused on the development and commercialization of topically administered drugs, primarily for the treatment of pain, using its proprietary drug delivery technologies. The company was founded by Jie Zhang, Theodore H. Stanley, Larry D. Rigby and Michael A. Ashburn in 1996 and is headquartered in Salt Lake City, UT. | Health Technology |
Vantia Ltd.
Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom. | Commercial Services |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- T. Crockett
- Experience